


WHAT IS CLAIMED IS:




1. A compound, or a pharmaceutically acceptable salt or solvate thereof,
 2. having the structure of **Formula (IA)** or **(IB)**:

**Formula (IA)****Formula (IB)**

wherein:

X is a bond, $-C(R^9)(R^{10})-$, $-N(R^{11})-$, $-O-$, $-S(O)_n-$, $-CH_2N(R^{11})-$, or $-CH_2O-$;


Y is a $-CH_2-$, $-CH_2CH_2-$, $-CH=CH-$, or $-CH_2OCH_2-$;



9. $(R^{12})_o$, wherein ring A is a 5- or 6-membered heteroaryl ring or a 5- or 6-membered
 10. heterocycloalkyl ring optionally substituted with halogen, cyano, $-N(R^{14})(R^{15})$, C_{1-6} alkyl, C_{1-6}
 11. alkoxy, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, C_{3-6} cycloalkyl, C_{3-6} cycloalkoxy, C_{3-6}
 12. halocycloalkyl, C_{3-6} halocycloalkoxy, heterocycloalkyl, aryl, heteroaryl, $-S(O)_n(R^{16})$, or $-SF_5$,
 13. wherein the heteroaryl or heterocycloalkyl ring contains 1, 2 or 3 heteroatoms selected from
 14. the group consisting of O, N or S;
 15. R^2 is hydrogen, deuterium, halogen, hydroxyl, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6}
 16. haloalkyl, C_{1-6} haloalkoxy, C_{3-6} cycloalkyl, C_{3-6} cycloalkoxy, C_{3-6} halocycloalkyl, C_{3-6}
 17. halocycloalkoxy, C_{1-6} alkylhydroxyl, heterocycloalkyl, aryl or heteroaryl;
 18. R^3 is halogen, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, C_{3-6}
 19. cycloalkyl, C_{3-6} cycloalkoxy, C_{3-6} halocycloalkyl, C_{3-6} halocycloalkoxy, C_{1-6} alkylhydroxyl,
 20. heterocycloalkyl, aryl or heteroaryl; or R^2 and R^3 combine to form a cycloalkyl or
 21. heterocycloalkyl ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl;

R^4 and R^5 are independently selected from hydrogen, deuterium, halogen, and C_{1-3} alkyl; or R^3 and R^4 combine to form a cycloalkyl or heterocycloalkyl ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl; or R^4 and R^5 combine to form a cycloalkyl or heterocycloalkyl ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl;

R^6 and R^7 are independently selected from hydrogen, deuterium, halogen, and C_{1-3} alkyl; or R^3 and R^7 combine to form a cycloalkyl or heterocycloalkyl ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl; or R^4 and R^6 combine to form a cycloalkyl or heterocycloalkyl ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl; or R^5 and R^7 combine to form a bond;



R^9 and R^{10} are independently selected from hydrogen, deuterium, halogen, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, C_{3-6} cycloalkyl, C_{3-6} cycloalkoxy, C_{3-6} halocycloalkyl, C_{3-6} halocycloalkoxy, heterocycloalkyl, aryl or heteroaryl; or R^3 and R^{10} combine to form a cycloalkyl or heterocycloalkyl ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl; or R^4 and R^{10} combine to form a cycloalkyl or heterocycloalkyl ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl; or R^6 and R^{10} combine to form a cycloalkyl or heterocycloalkyl ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl; or R^9 and R^{10} combine to form a cycloalkyl or heterocycloalkyl ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl;

R^{11} is hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-6} cycloalkyl, C_{3-6} halocycloalkyl, heterocycloalkyl aryl or heteroaryl; or R^3 and R^{11} combine to form a heterocycloalkyl ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl; or R^4 and R^{11} combine to form a heterocycloalkyl ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl; or R^6 and R^{11} combine to form a heterocycloalkyl ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl;

each R^{12} is independently selected from hydroxyl, halogen, cyano, $-N(R^{14})(R^{15})$, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, C_{3-6} cycloalkyl, C_{3-6} cycloalkoxy, C_{3-6} halocycloalkyl, C_{3-6} halocycloalkoxy, C_{1-6} alkylhydroxyl, heterocycloalkyl, aryl, heteroaryl, $-S(O)_n(R^{16})$, or $-SF_5$; or R^3 and one R^{12} combine to form a cycloalkyl or heterocycloalkyl ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl; or R^{10} and one R^{12} combine to form a cycloalkyl or heterocycloalkyl ring optionally substituted with

54 halogen, C₁₋₆ alkyl, or C₃₋₆ cycloalkyl; or R¹¹ and one R¹² combine to form a heterocycloalkyl
 55 ring optionally substituted with halogen, C₁₋₆ alkyl, or C₃₋₆ cycloalkyl;

56 R¹³ is hydrogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, C₃₋₆ halocycloalkyl,
 57 heterocycloalkyl, aryl or heteroaryl;

58 R¹⁴ and R¹⁵ are independently selected from hydrogen, C₁₋₆ alkyl, C₁₋₆
 59 haloalkyl, C₃₋₆ cycloalkyl, C₃₋₆ halocycloalkyl, heterocycloalkyl, aryl or heteroaryl; or R¹⁴ and
 60 R¹⁵ combine to form a heterocycloalkyl ring optionally substituted with halogen, C₁₋₆ alkyl, or
 61 C₃₋₆ cycloalkyl;


62 R¹⁶ is C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, C₃₋₆ halocycloalkyl,
 63 heterocycloalkyl, aryl or heteroaryl;

64 m is 0 or 1;

65 n is 0, 1, or 2; and

66 o is 0, 1, 2, or 3.

1 2. The compound of claim 1, or a pharmaceutically acceptable salt or
 2 solvate thereof, having the structure of **Formula (IIA)** or **(IIB)**:




3 **Formula (IIA)**

Formula (IIB)

4 wherein:

5 X is a bond, -C(R⁹)(R¹⁰)-, -N(R¹¹)-, -O-, -S(O)_n-, -CH₂N(R¹¹)-, or -CH₂O-;

6 Y is a -CH₂-, -CH₂CH₂-, -CH=CH-, or -CH₂OCH₂-;




10 heterocycloalkyl ring optionally substituted with halogen, cyano, -N(R¹⁴)(R¹⁵), C₁₋₆ alkyl, C₁₋

6 alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkoxy, C₃₋₆ halocycloalkyl, C₃₋₆ halocycloalkoxy, heterocycloalkyl, aryl, heteroaryl, -S(O)_n(R¹⁶), or -SF₅, wherein the heteroaryl or heterocycloalkyl ring contains 1, 2 or 3 heteroatoms selected from the group consisting of O, N or S;

R² is hydrogen, deuterium, halogen, hydroxyl, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkoxy, C₃₋₆ halocycloalkyl, C₃₋₆ halocycloalkoxy, C₁₋₆ alkylhydroxyl, heterocycloalkyl, aryl or heteroaryl;

R³ is halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkoxy, C₃₋₆ halocycloalkyl, C₃₋₆ halocycloalkoxy, C₁₋₆ alkylhydroxyl, heterocycloalkyl, aryl or heteroaryl; or R² and R³ combine to form a cycloalkyl or heterocycloalkyl ring optionally substituted with halogen, C₁₋₆ alkyl, or C₃₋₆ cycloalkyl;



R⁹ and R¹⁰ are independently selected from hydrogen, deuterium, halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkoxy, C₃₋₆ halocycloalkyl, C₃₋₆ halocycloalkoxy, heterocycloalkyl, aryl or heteroaryl; or R³ and R¹⁰ combine to form a cycloalkyl or heterocycloalkyl ring optionally substituted with halogen, C₁₋₆ alkyl, or C₃₋₆ cycloalkyl; or R⁹ and R¹⁰ combine to form a cycloalkyl or heterocycloalkyl ring optionally substituted with halogen, C₁₋₆ alkyl, or C₃₋₆ cycloalkyl;

R¹¹ is hydrogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, C₃₋₆ halocycloalkyl, heterocycloalkyl aryl or heteroaryl; or R³ and R¹¹ combine to form a heterocycloalkyl ring optionally substituted with halogen, C₁₋₆ alkyl, or C₃₋₆ cycloalkyl;

each R¹² is independently selected from hydroxyl, halogen, cyano, -N(R¹⁴)(R¹⁵), C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkoxy, C₃₋₆ halocycloalkyl, C₃₋₆ halocycloalkoxy, C₁₋₆ alkylhydroxyl, heterocycloalkyl, aryl, heteroaryl, -S(O)_n(R¹⁶), or -SF₅; or R³ and one R¹² combine to form a cycloalkyl or heterocycloalkyl ring optionally substituted with halogen, C₁₋₆ alkyl, or C₃₋₆ cycloalkyl; or R¹⁰ and one R¹² combine to form a cycloalkyl or heterocycloalkyl ring optionally substituted with halogen, C₁₋₆ alkyl, or C₃₋₆ cycloalkyl; or R¹¹ and one R¹² combine to form a heterocycloalkyl ring optionally substituted with halogen, C₁₋₆ alkyl, or C₃₋₆ cycloalkyl;

R¹³ is hydrogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, C₃₋₆ halocycloalkyl, heterocycloalkyl, aryl or heteroaryl;

R^{14} and R^{15} are independently selected from hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-6} cycloalkyl, C_{3-6} halocycloalkyl, heterocycloalkyl, aryl or heteroaryl; or R^{14} and R^{15} combine to form a heterocycloalkyl ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl;


R^{16} is C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-6} cycloalkyl, C_{3-6} halocycloalkyl, heterocycloalkyl, aryl or heteroaryl;

m is 0 or 1;

n is 0, 1, or 2; and

o is 0, 1, 2, or 3.




3. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, having the structure of **Formula (III)**:



Formula (III)

wherein:


X is a bond, $-C(R^9)(R^{10})-$, $-N(R^{11})-$, $-O-$, $-S(O)_n-$, $-CH_2N(R^{11})-$, or $-CH_2O-$;



$(R^{12})_o$, wherein ring A is a 5- or 6-membered heteroaryl ring or a 5- or 6-membered heterocycloalkyl ring optionally substituted with halogen, cyano, $-N(R^{14})(R^{15})$, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, C_{3-6} cycloalkyl, C_{3-6} cycloalkoxy, C_{3-6} halocycloalkyl, C_{3-6} halocycloalkoxy, heterocycloalkyl, aryl, heteroaryl, $-S(O)_n(R^{16})$, or $-SF_5$, wherein the heteroaryl or heterocycloalkyl ring contains 1, 2 or 3 heteroatoms selected from the group consisting of O, N or S;

14 R^2 is hydrogen, deuterium, halogen, hydroxyl, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6}
 15 haloalkyl, C_{1-6} haloalkoxy, C_{3-6} cycloalkyl, C_{3-6} cycloalkoxy, C_{3-6} halocycloalkyl, C_{3-6}
 16 halocycloalkoxy, C_{1-6} alkylhydroxyl, heterocycloalkyl, aryl or heteroaryl;

17 R^3 is halogen, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, C_{3-6}
 18 cycloalkyl, C_{3-6} cycloalkoxy, C_{3-6} halocycloalkyl, C_{3-6} halocycloalkoxy, C_{1-6} alkylhydroxyl,
 19 heterocycloalkyl, aryl or heteroaryl; or R^2 and R^3 combine to form a cycloalkyl or
 20 heterocycloalkyl ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl;

21 R^8 is ; or

22 R^9 and R^{10} are independently selected from hydrogen, deuterium, halogen,
 23 C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, C_{3-6} cycloalkyl, C_{3-6} cycloalkoxy, C_{3-6}
 24 halocycloalkyl, C_{3-6} halocycloalkoxy, heterocycloalkyl, aryl or heteroaryl; or R^3 and R^{10}
 25 combine to form a cycloalkyl or heterocycloalkyl ring optionally substituted with halogen,
 26 C_{1-6} alkyl, or C_{3-6} cycloalkyl; or R^9 and R^{10} combine to form a cycloalkyl or heterocycloalkyl
 27 ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl;

28 R^{11} is hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-6} cycloalkyl, C_{3-6} halocycloalkyl,
 29 heterocycloalkyl aryl or heteroaryl; or R^3 and R^{11} combine to form a heterocycloalkyl ring
 30 optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl;

31 each R^{12} is independently selected from hydroxyl, halogen, cyano,
 32 $-N(R^{14})(R^{15})$, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, C_{3-6} cycloalkyl, C_{3-6}
 33 cycloalkoxy, C_{3-6} halocycloalkyl, C_{3-6} halocycloalkoxy, C_{1-6} alkylhydroxyl, heterocycloalkyl,
 34 aryl, heteroaryl, $-S(O)_n(R^{16})$, or $-SF_5$; or R^3 and one R^{12} combine to form a cycloalkyl or
 35 heterocycloalkyl ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl; or R^{10}
 36 and one R^{12} combine to form a cycloalkyl or heterocycloalkyl ring optionally substituted with
 37 halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl; or R^{11} and one R^{12} combine to form a heterocycloalkyl
 38 ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl;

39 R^{13} is hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-6} cycloalkyl, C_{3-6} halocycloalkyl,
 40 heterocycloalkyl, aryl or heteroaryl;

41 R^{14} and R^{15} are independently selected from hydrogen, C_{1-6} alkyl, C_{1-6}
 42 haloalkyl, C_{3-6} cycloalkyl, C_{3-6} halocycloalkyl, heterocycloalkyl, aryl or heteroaryl; or R^{14} and
 43 R^{15} combine to form a heterocycloalkyl ring optionally substituted with halogen, C_{1-6} alkyl, or
 44 C_{3-6} cycloalkyl;

45 R^{16} is C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-6} cycloalkyl, C_{3-6} halocycloalkyl,
 46 heterocycloalkyl, aryl or heteroaryl;
 47 m is 0 or 1;
 48 n is 0, 1, or 2; and
 49 o is 0, 1, 2, or 3.

1 4. The compound of claim 1, or a pharmaceutically acceptable salt or
 2 solvate thereof, wherein X is a bond.

1 5. The compound of claim 1, or a pharmaceutically acceptable salt or
 2 solvate thereof, wherein X is $-C(R^9)(R^{10})-$.

1 6. The compound of claim 1, or a pharmaceutically acceptable salt or
 2 solvate thereof, wherein X is $-N(R^{11})-$.


1 7. The compound of claim 1, or a pharmaceutically acceptable salt or
 2 solvate thereof, wherein X is $-O-$.


1 8. The compound of claim 1, or a pharmaceutically acceptable salt or
 2 solvate thereof, wherein X is $-S-$.

1 9. The compound of claim 1, or a pharmaceutically acceptable salt or
 2 solvate thereof, wherein X is $-S(O)-$.

1 10. The compound of claim 1, or a pharmaceutically acceptable salt or
 2 solvate thereof, wherein X is $-S(O)_2-$.

1 11. The compound of claim 1, or a pharmaceutically acceptable salt or





1 12. The compound of claim 1, or a pharmaceutically acceptable salt or
 2 solvate thereof, wherein R^2 is hydrogen, -F, -CH₃, -CH₂CH₃, -CF₂H, -CF₃, -CH₂OH,
 3 -C(CH₃)₂OH, phenyl, or cyclopropyl.

1 13. The compound of claim 1, or a pharmaceutically acceptable salt or
 2 solvate thereof, wherein R^3 is -F, -CH₃, -CH₂CH₃, -CF₂H, -CF₃, -CH₂OH, -C(CH₃)₂OH,
 3 phenyl, or cyclopropyl.

1 14. The compound of claim 1, or a pharmaceutically acceptable salt or
 2 solvate thereof, wherein R^2 and R^3 combine to form a cyclopropyl, cyclobutyl, or cyclopentyl
 3 ring.

1 15. The compound of claim 1, or a pharmaceutically acceptable salt or
 2 solvate thereof, wherein R^2 and R^3 combine to form an oxetanyl or tetrahydrofuranyl ring.

1 16. The compound of claim 1, or a pharmaceutically acceptable salt or
 2 solvate thereof, wherein m is 0.

1 17. The compound of claim 1, or a pharmaceutically acceptable salt or
 2 solvate thereof, wherein m is 1.


1 18. The compound of claim 1, or a pharmaceutically acceptable salt or
 2 solvate thereof, wherein o is 0.


1 19. The compound of claim 1, or a pharmaceutically acceptable salt or
 2 solvate thereof, wherein o is 1.


1 20. The compound of claim 1, or a pharmaceutically acceptable salt or
 2 solvate thereof, wherein o is 2.


1 22. The compound of claim 1, or a pharmaceutically acceptable salt or


1 23. A compound selected from:



































1 24. A pharmaceutical composition comprising a compound of any one of
2 claims 1-23, or a pharmaceutically acceptable salt or solvate thereof, and at least one
3 pharmaceutically acceptable excipient.

1 25. A method of treating a neurodegenerative disorder in a subject in need
2 thereof, comprising administering to the subject a therapeutically effective amount of a
3 compound of any one of claims 1-23, or a pharmaceutically acceptable salt or solvate thereof.

1 26. The method of claim 25, further comprising the administration of one
2 or more immunomodulatory agents.

1 27. The method of claim 26, wherein the one or more immunomodulatory
2 agents are selected from: an IFN- β 1 molecule; a corticosteroid; a polymer of glutamic acid,
3 lysine, alanine and tyrosine or glatiramer; an antibody or fragment thereof against alpha-4
4 integrin or natalizumab; an anthracenedione molecule or mitoxantrone; a fingolimod or
5 FTY720 or other S1P1 functional modulator; a dimethyl fumarate or other NRF2 functional
6 modulator; an antibody to the alpha subunit of the IL-2 receptor of T cells (CD25) or
7 daclizumab; an antibody against CD52 or alemtuzumab; an antibody against CD20 or
8 ocrelizumab; and an inhibitor of a dihydroorotate dehydrogenase or teriflunomide.

1 28. A method of treating a demyelinating disease in a subject in need
2 thereof, comprising administering to the subject a therapeutically effective amount of a
3 compound of any one of claims 1-23, or a pharmaceutically acceptable salt or solvate thereof.

1 29. The method of claim 28, wherein the demyelinating disease is a
2 demyelinating disease of the central nervous system.

1 30. The method of claim 29, wherein the demyelinating disease is multiple
2 sclerosis.

1 31. The method of claim 28, wherein the demyelinating disease is a
2 demyelinating disease of the peripheral nervous system.

1 32. The method of claim 28, further comprising the administration of one
2 or more immunomodulatory agents.

1 33. The method of claim 32, wherein the one or more immunomodulatory
2 agents are selected from: an IFN- β 1 molecule; a corticosteroid; a polymer of glutamic acid,
3 lysine, alanine and tyrosine or glatiramer; an antibody or fragment thereof against alpha-4
4 integrin or natalizumab; an anthracenedione molecule or mitoxantrone; a fingolimod or
5 FTY720 or other S1P1 functional modulator; a dimethyl fumarate or other NRF2 functional
6 modulator; an antibody to the alpha subunit of the IL-2 receptor of T cells (CD25) or
7 daclizumab; an antibody against CD52 or alemtuzumab; an antibody against CD20 or
8 ocrelizumab; and an inhibitor of a dihydroorotate dehydrogenase or teriflunomide.

1 34. A method of treating a neuropathic disease, optionally a peripheral
2 neuropathy, in a subject in need thereof, comprising administering to the subject a
3 therapeutically effective amount of a compound of any one of claims 1-23, or a
4 pharmaceutically acceptable salt or solvate thereof.

1 35. The method of claim 34, wherein the neuropathic disease is diabetic
2 neuropathy.

1 36. The method of claim 34, further comprising the administration of one
2 or more immunomodulatory agents.

1 37. The method of claim 36, wherein the one or more immunomodulatory
2 agents are selected from: an IFN- β 1 molecule; a corticosteroid; a polymer of glutamic acid,
3 lysine, alanine and tyrosine or glatiramer; an antibody or fragment thereof against alpha-4
4 integrin or natalizumab; an anthracenedione molecule or mitoxantrone; a fingolimod or
5 FTY720 or other S1P1 functional modulator; a dimethyl fumarate or other NRF2 functional
6 modulator; an antibody to the alpha subunit of the IL-2 receptor of T cells (CD25) or
7 daclizumab; an antibody against CD52 or alemtuzumab; an antibody against CD20 or
8 ocrelizumab; and an inhibitor of a dihydroorotate dehydrogenase or teriflunomide.

1 38. A method of modulating muscarinic acetylcholine receptor M₁ activity
2 in a subject comprising administering to the subject a compound of any one of claims 1-23,
3 or a pharmaceutically acceptable salt or solvate thereof.

1 39. The method of claim 38, wherein the compound acts as a selective M₁
2 antagonist.